NCT04451291已完成不适用
DSC-COVID-19: An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 3
- 主要终点
- Number of ventilator free days following infusion of decidual stromal cells
研究概览
简要总结
This is a research study to see how safe and effective decidual stromal cells are in treating patients with respiratory failure (breathing problem where not enough oxygen is passed from the lungs into the blood) caused by COVID-19.
详细描述
COVID-19 viral infectious disease that has lead to high numbers of critically ill patients or death due to respiratory failure.
Decidual Stromal Cells (DSC) may be useful in the treatment of acute respiratory distress syndrome (ARDS) by reducing lung inflammation and then time that patients require help with breathing (mechanical ventilation).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide informed consent for participation in the study, either by the participant themselves or by the legally acceptable representative (LAR)
- •Virological diagnosis of SARS-CoV-2 infection (PCR)
- •Acute respiratory distress syndrome (ARDS) not due to cardiac causes
- •Receiving mechanical ventilation
排除标准
- •Severe comorbidity with life expectancy <3 months according to investigators assessment
- •Currently receiving extracorporeal membrane oxygenation (ECMO)
- •Patients with established positive bacterial blood cultures prior to enrollment or suspicion of superimposed bacterial pneumonia
- •Patients with diagnosed significant pulmonary embolism or deep vein thrombosis in the previous 3 months
- •Patients who have been intubated for more than 48 hours
- •Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins
- •Acute co-morbidity within 7 days before inclusion such as stroke
- •History of severe chronic history of heart disease, recent myocardial infarction or unstable angina, lung disease (requiring home oxygen), pulmonary hypertension, or liver comorbidities
- •Malignancy that requires treatment in the previous two years (excluding non-melanoma skin malignancies treated by excision, or cryotherapy)
- •History of immunosuppression (immunomodulators or anti-rejection drugs in past year, or active disease, autoimmune disease on treatment, transplant recipients) or anaphylaxis
- •Refusal of blood products
- •Severe co-morbidity/co-morbidities which in the opinion of the investigators would compromise safety assessments
- •Pregnant or breast-feeding
- •Actively participating on another trial of an investigational agent for ARDS
- •Unacceptable laboratory blood tests for alanine aminotransferase (ALT)/aspartate aminotransferase (AST), neutrophils, or platelets
研究组 & 干预措施
Decidual Stromal Cells (DSC)
Experimental
Participants will receive one dose of DSC at 1x10^6/kg. A second dose may be given sometime between Day 5 and Day 8 if the participant's condition improves.
干预措施: Decidual Stromal Cells (DSC) (Biological)
结局指标
主要结局
Number of ventilator free days following infusion of decidual stromal cells
时间窗: 28 days
次要结局
- Mean PaO2/FiO2 as compared to patient baseline(180 days)
- Mortality rate from COVID-19(180 days)
- Average number of days of hospital admittance(180 days)
- All-cause morality rate(180 days)
- Average number of days in ICU(180 days)
- Average viral clearance(180 days)
- Average number of days of supplemental oxygenation(180 days)
- Average number of day without supplemental oxygen(180 days)
- Average days not requiring vasopressors(180 days)
- Overall survival rate(180 days)
- Mortality rate from COVID-19(28 days)
- Mortality rate from COVID-19(60 days)
- All-cause morality rate(28 days)
- All-cause morality rate(60 days)
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
1 期
A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation SettingDecidual Stromal CellsStem Cell TransplantationInflammationAcute Lung InjuryNCT02175303Karolinska Institutet25
已完成
1 期
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 PatientsCorona Virus InfectionSARCovid19NCT04535856Ina-Respond9
Unknown
2 期
Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLCNon Small Cell Lung CancerNCT02669719Shanghai Chest Hospital70
Unknown
1 期
Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 StudyGraft vs Host DiseaseNCT02172937Karolinska Institutet50
Unknown
1 期
A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host DiseaseGraft vs Host DiseaseNCT02172924Karolinska Institutet30